Results:
Of the 2,049 IVF cycles included, dual trigger was most commonly used (1172 cycles (57.3%)) followed by R-hCG:498 cycles (24.3%), GnRH agonist was administered least (178 cycles (8.6%)) (P-hCG: 201 cycles (9.8%)) (Table 1) . Overall, 62.9% of oocytes reached the MII stage of development. When using P-hCG as a control group, significant differences between the MII rates per group were observed. (p <0.0001) (Figure 1 ). When adjusted for age, body mass index and the total number of eggs retrieved; no difference was observed between trigger method and the rate of MII oocyte formation (Table 2) (Figure 1 ).
Conclusions:
The GnRH agonist and dual triggers has proven to be a valuable option when treating patients who are at risk of OHSS and offers a greater margin of safety compared with the hCG trigger protocol. The study demonstrates no significant differences in the number of mature oocytes at retrieval when comparing different trigger strategies. Trigger medication choice can be based on patient-specific clinical characteristics that can reassure a decreased risk of OHSS without compromising oocyte maturity rates.
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